Video

Dr. Cohen on the Goals of the SPEARHEAD-2 Trial in Head and Neck Cancer

Author(s):

Ezra Cohen, MD, FRCPSC, FASCO, discusses the goals of the phase 2 SPEARHEAD-2 trial in head and neck cancer.

Ezra Cohen, MD, FRCPSC, FASCO, chief of the Division of Hematology-Oncology, and a medical oncologist at the University of California, San Diego Health, discusses the goals of the phase 2 SPEARHEAD-2 trial (NCT04408898) in head and neck cancer.

The pilot SPEARHEAD-2 trial is currently enrolling patients with recurrent or metastatic head and neck cancer, says Cohen. The goal of the study is to identify the potential use of ADP-A2M4 plus pembrolizumab (Keytruda) as a rescue therapy for patients who are unresponsive to PD-1 inhibitors alone. There currently aren’t effective options for this subgroup of patients, Cohen explains.

However, eligible patients must be checkpoint inhibitor naïve, PD-L1 positive, MAGE-A4 expressors, and human leukocyte antigen-A*02 positive, says Cohen. Because that subpopulation of patients with recurrent head and neck cancer is limited, clinical trial accrual could be challenging, concludes Cohen.

Related Videos
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD